NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results and business updates for the quarter ended March 31, 2022.
Harmony Biosciences reported a strong first quarter in 2022, with WAKIX net revenue reaching $85.3 million, a 43% increase compared to the same period in 2021, and GAAP net income of $21.5 million, or $0.35 per diluted share.
- WAKIX net revenue reached $85.3 million, a 43% increase compared to Q1 2021.
- WAKIX surpassed $500 million in cumulative net revenue since launch.
- Phase 3 clinical trial was initiated in patients with Idiopathic Hypersomnia.
- GAAP net income was $21.5 million, or $0.35 per diluted share.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$85.3M
Revenue by segment
Harmony Biosciences · $85.3M total across 1 segment · Q1 2022
- WAKIX Net Product Revenue$85.3M+43.0%100.0%
Forward guidance
Harmony Biosciences is focused on acquiring new assets and evolving into a leading rare neurology company with a broad portfolio of innovative products. Topline data from the Phase 2 proof-of-concept trial in PWS is anticipated in the second half of 2022, and DM1 topline data is expected in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro